Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TYR | P14679 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 3/20 | 0.31 |
| ▸ | RXRA | P19793 | 2/20 | 0.31 |
| ▸ | RXRG | P48443 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL248234 | 0.85 | POLB (0.39) | POLBGABRA1GABRB2HTR1DTSHR | |
| SCHEMBL8604961 | 0.82 | ALOX15 (0.39) | TSHRALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL5134086 | 0.76 | KIF11 (0.48) | POLBTSHRALDH1A1HPGDALOX15 | |
| SCHEMBL455828 | 0.74 | RAPGEF4 (0.38) | TSHRALDH1A1HPGDALOX15TDP1 | |
| SCHEMBL4192680 | 0.74 | TSHR (0.33) | TSHR | |
| SCHEMBL93161 | 0.73 | GABRA1 (0.69) | POLBGABRA1GABRB2HTR1DTSHR | |
| SCHEMBL20339731 | 0.72 | SHBG (0.43) | ALDH1A1ALOX15HSD17B10MAPTMEN1 | |
| SCHEMBL201608 | 0.71 | POLB (0.52) | POLBGABRA1GABRB2HTR1DTSHR | |
| SCHEMBL150439 | 0.71 | GABRA1 (0.43) | POLBGABRA1GABRB2HTR1DTSHR | |
| SCHEMBL288176 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 355 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114423739-B | Improved enantioselective hydrogenation of 4-substituted 1, 2-dihydroquinolines in the presence of chiral iridium catalysts and additives | 拜耳公司 | 2024-06-25 | — | — | CN | claimed |
| CN-111902399-B | Enantioselective hydrogenation of 4-substituted 1, 2-dihydroquinolines in the presence of chiral iridium catalysts | 拜耳公司 | 2023-11-28 | — | — | CN | claimed |
| EP-3774735-B1 | ENANTIOSELECTIVE HYDROGENATION OF 4-SUBSTITUTED 1,2-DIHYDROQUINOLINES IN PRESENCE OF A CHIRAL IRIDIUM CATALYST | BAYER AG (DE) | 2023-09-13 | — | — | EP | claimed |
| CN-116710116-A | Beta-sheet femoral bridge peptide | Ｘｅｎｏ－Ｉｎｔｅｒｆａｃｅ株式会社 | 2023-09-05 | — | — | CN | claimed |
| WO-2023070120-A1 | KETOAMIDES FOR TREATING MALIGNANCY | BIOTHERYX, INC. (US) | 2023-04-27 | — | — | WO | claimed |
| US-11345712-B2 | Protein-targeting compounds and pharmaceutical compositions thereof, and their therapeutic applications | BIOTHERYX, INC. (US) | 2022-05-31 | — | — | US | claimed |
| CN-114502543-A | Targeted protein compounds, pharmaceutical compositions and therapeutic applications thereof | 拜欧斯瑞克斯公司 | 2022-05-13 | — | — | CN | claimed |
| CN-114423739-A | Improved enantioselective hydrogenation of 4-substituted 1, 2-dihydroquinolines in the presence of chiral iridium catalysts and additives | 拜耳公司 | 2022-04-29 | — | — | CN | claimed |
| WO-2021058457-A1 | IMPROVED ENANTIOSELECTIVE HYDROGENATION OF 4-SUBSTITUTED 1,2-DIHYDROQUINOLINES IN PRESENCE OF A CHIRAL IRIDIUM CATALYST AND AN ADDITIVE | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-01 | — | — | WO | claimed |
| EP-3774735-A1 | ENANTIOSELECTIVE HYDROGENATION OF 4-SUBSTITUTED 1,2-DIHYDROQUINOLINES IN PRESENCE OF A CHIRAL IRIDIUM CATALYST | Bayer Aktiengesellschaft (DE) | 2021-02-17 | — | — | EP | claimed |
| EP-0766664-A2 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1997-04-09 | — | — | EP | claimed |
| EP-0740652-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1996-11-06 | — | — | EP | claimed |
| WO-1995035275-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-12-28 | — | — | WO | claimed |
| WO-1995019956-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-07-27 | — | — | WO | claimed |
| EP-0156514-A2 | Photoconductive devices containing perylene dye compositions | XEROX CORPORATION (US) | 1985-10-02 | — | — | EP | claimed |
| EP-0073413-B1 | ACYLPHOSPHINE OXIDE COMPOUNDS AND THEIR USE | BASF Aktiengesellschaft (DE) | 1984-12-05 | — | — | EP | claimed |
| EP-0062839-B1 | ACYLPHOSPHINE COMPOUNDS AND THEIR USE | BASF Aktiengesellschaft (DE) | 1984-11-21 | — | — | EP | claimed |
| US-4447520-A | PHOTOINITIATOR FOR PHOTOPOLYMERIZATION | BASF AKTIENGESELLSCHAFT (DE) | 1984-05-08 | — | — | US | claimed |
| EP-0073413-A2 | Acylphosphine oxide compounds and their use | BASF Aktiengesellschaft (DE) | 1983-03-09 | — | — | EP | claimed |
| EP-0062839-A1 | Acylphosphine compounds and their use | BASF Aktiengesellschaft (DE) | 1982-10-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345712-B2 | Protein-targeting compounds and pharmaceutical compositions thereof, and their therapeutic applications | HSP90B1, EIF4EBP1, SERPINA6 | POLB 3667/4885GABRA1 3386/4885GABRB2 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.